Anne-Marie Wills1, Jane Hubbard2, Eric A Macklin3, Jonathan Glass4, Rup Tandan5, Ericka P Simpson6, Benjamin Brooks7, Deborah Gelinas8, Hiroshi Mitsumoto9, Tahseen Mozaffar10, Gregory P Hanes11, Shafeeq S Ladha12, Terry Heiman-Patterson13, Jonathan Katz14, Jau-Shin Lou15, Katy Mahoney16, Daniela Grasso16, Robert Lawson16, Hong Yu16, Merit Cudkowicz16. 1. Department of Neurology and the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: awills@partners.org. 2. Harvard Catalyst/Massachusetts General Hospital Clinical Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 3. Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 4. Emory University School of Medicine, Atlanta, GA, USA. 5. University of Vermont, Burlington, VT, USA. 6. Methodist Neurological Institute, Houston, TX, USA. 7. Carolinas Medical Center Neuromuscular/ALS-MDA Center, Charlotte, NC, USA. 8. Saint Mary's Health Care, Grand Rapids, MI, USA. 9. Columbia Presbyterian Medical Center, New York, NY, USA. 10. University of California at Irvine, Irvine, CA, USA. 11. Sarasota Memorial Hospital, Sarasota, FL, USA. 12. Barrow Neurological Institute/St Joseph's Hospital and Medical Center, Phoenix, AZ, USA. 13. Drexel University, Philadelphia, PA, USA. 14. California Pacific Medical Center, University of California at San Francisco, San Francisco, CA, USA. 15. Oregon Health and Science University, Portland, OR, USA. 16. Department of Neurology and the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Amyotrophic lateral sclerosis is a fatal neurodegenerative disease with few therapeutic options. Mild obesity is associated with greater survival in patients with the disease, and calorie-dense diets increased survival in a mouse model. We aimed to assess the safety and tolerability of two hypercaloric diets in patients with amyotrophic lateral sclerosis receiving enteral nutrition. METHODS: In this double-blind, placebo-controlled, randomised phase 2 clinical trial, we enrolled adults with amyotrophic lateral sclerosis from participating centres in the USA. Eligible participants were aged 18 years or older with no history of diabetes or liver or cardiovascular disease, and who were already receiving percutaneous enteral nutrition. We randomly assigned participants (1:1:1) using a computer-generated list of random numbers to one of three dietary interventions: replacement calories using an isocaloric tube-fed diet (control), a high-carbohydrate hypercaloric tube-fed diet (HC/HC), or a high-fat hypercaloric tube-fed diet (HF/HC). Participants received the intervention diets for 4 months and were followed up for 5 months. The primary outcomes were safety and tolerability, analysed in all patients who began their study diet. This trial is registered with ClinicalTrials.gov, number NCT00983983. FINDINGS:Between Dec 14, 2009, and Nov 2, 2012, we enrolled 24 participants, of whom 20 started their study diet (six in the control group, eight in the HC/HC group, and six in the HF/HC group). One patient in the control group, one in the HC/HC group, and two in the HF/HC group withdrew consent before receiving the intervention. Participants who received the HC/HC diet had a smaller total number of adverse events than did those in the other groups (23 in the HC/HC group vs 42 in the control group vs 48 in the HF/HC group; overall, p=0.06; HC/HC vs control, p=0.06) and significantly fewer serious adverse events than did those on the control diet (none vs nine; p=0.0005). Fewer patients in the HC/HC group discontinued their study diet due to adverse events (none [0%] of eight in the HC/HC group vs three [50%] of six in the control group). During the 5 month follow-up, no deaths occurred in the nine patients assigned to the HC/HC diet compared with three deaths (43%) in the seven patients assigned to the control diet (log-rank p=0.03). Adverse events, tolerability, deaths, and disease progression did not differ significantly between the HF/HC group and the control group. INTERPRETATION: Our results provide preliminary evidence that hypercaloric enteral nutrition is safe and tolerable in patients with amyotrophic lateral sclerosis, and support the study of nutritional interventions in larger randomised controlled trials at earlier stages of the disease. FUNDING: Muscular Dystrophy Association, National Center for Research Resources, National Institutes of Health, and Harvard NeuroDiscovery Center.
RCT Entities:
BACKGROUND:Amyotrophic lateral sclerosis is a fatal neurodegenerative disease with few therapeutic options. Mild obesity is associated with greater survival in patients with the disease, and calorie-dense diets increased survival in a mouse model. We aimed to assess the safety and tolerability of two hypercaloric diets in patients with amyotrophic lateral sclerosis receiving enteral nutrition. METHODS: In this double-blind, placebo-controlled, randomised phase 2 clinical trial, we enrolled adults with amyotrophic lateral sclerosis from participating centres in the USA. Eligible participants were aged 18 years or older with no history of diabetes or liver or cardiovascular disease, and who were already receiving percutaneous enteral nutrition. We randomly assigned participants (1:1:1) using a computer-generated list of random numbers to one of three dietary interventions: replacement calories using an isocaloric tube-fed diet (control), a high-carbohydrate hypercaloric tube-fed diet (HC/HC), or a high-fat hypercaloric tube-fed diet (HF/HC). Participants received the intervention diets for 4 months and were followed up for 5 months. The primary outcomes were safety and tolerability, analysed in all patients who began their study diet. This trial is registered with ClinicalTrials.gov, number NCT00983983. FINDINGS: Between Dec 14, 2009, and Nov 2, 2012, we enrolled 24 participants, of whom 20 started their study diet (six in the control group, eight in the HC/HC group, and six in the HF/HC group). One patient in the control group, one in the HC/HC group, and two in the HF/HC group withdrew consent before receiving the intervention. Participants who received the HC/HC diet had a smaller total number of adverse events than did those in the other groups (23 in the HC/HC group vs 42 in the control group vs 48 in the HF/HC group; overall, p=0.06; HC/HC vs control, p=0.06) and significantly fewer serious adverse events than did those on the control diet (none vs nine; p=0.0005). Fewer patients in the HC/HC group discontinued their study diet due to adverse events (none [0%] of eight in the HC/HC group vs three [50%] of six in the control group). During the 5 month follow-up, no deaths occurred in the nine patients assigned to the HC/HC diet compared with three deaths (43%) in the seven patients assigned to the control diet (log-rank p=0.03). Adverse events, tolerability, deaths, and disease progression did not differ significantly between the HF/HC group and the control group. INTERPRETATION: Our results provide preliminary evidence that hypercaloric enteral nutrition is safe and tolerable in patients with amyotrophic lateral sclerosis, and support the study of nutritional interventions in larger randomised controlled trials at earlier stages of the disease. FUNDING: Muscular Dystrophy Association, National Center for Research Resources, National Institutes of Health, and Harvard NeuroDiscovery Center.
Authors: James D Berry; Robert Miller; Dan H Moore; Merit E Cudkowicz; Leonard H van den Berg; Douglas A Kerr; Yingwen Dong; Evan W Ingersoll; Donald Archibald Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2013-01-17 Impact factor: 4.092
Authors: Ronit Reich-Slotky; Jinsy Andrews; Bin Cheng; Richard Buchsbaum; Diane Levy; Petra Kaufmann; John L P Thompson Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2013-03-01 Impact factor: 4.092
Authors: Johannes Dorst; Luc Dupuis; Susanne Petri; Katja Kollewe; Susanne Abdulla; Joachim Wolf; Markus Weber; David Czell; Christian Burkhardt; Frank Hanisch; Stefan Vielhaber; Thomas Meyer; Gabriele Frisch; Dagmar Kettemann; Torsten Grehl; Bertold Schrank; Albert C Ludolph Journal: J Neurol Date: 2015-01-25 Impact factor: 4.849
Authors: H Blasco; F Patin; S Molinier; P Vourc'h; O Le Tilly; S Bakkouche; C R Andres; V Meininger; P Couratier; P Corcia Journal: Eur J Clin Nutr Date: 2017-04-19 Impact factor: 4.016
Authors: Marianthi-Anna Kioumourtzoglou; Ran S Rotem; Ryan M Seals; Ole Gredal; Johnni Hansen; Marc G Weisskopf Journal: JAMA Neurol Date: 2015-08 Impact factor: 18.302
Authors: Carlayne E Jackson; April L McVey; Stacy Rudnicki; Mazen M Dimachkie; Richard J Barohn Journal: Neurol Clin Date: 2015-11 Impact factor: 3.806
Authors: Gopalakrishnan Natarajan; Curtis Perriotte-Olson; Fatema Bhinderwala; Robert Powers; Cyrus V Desouza; Geoffrey A Talmon; Jiang Yuhang; Matthew C Zimmerman; Alexander V Kabanov; Viswanathan Saraswathi Journal: Transl Res Date: 2017-08-15 Impact factor: 7.012